ALXN1210 Versus Eculizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab
Study Identifier:
ALXN1210-PNH-302
ClinicalTrials.gov Identifier:
EudraCT Identifier:
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Study Complete
Study Details
Medical Condition
- Unmapped
Study Drug
- Biological: Ravulizumab
- Biological: Eculizumab
Date
May 2017 - Feb 2022
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18+ years
Requirements Information
Sex
Female & Male
Age
18+ years
Study Details
Medical Condition
- Unmapped
Study Drug
- Biological: Ravulizumab
- Biological: Eculizumab
Date
May 2017 - Feb 2022
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18+ years years
Requirements Information
Protocol Summary
The primary purpose of this study was to assess the noninferiority of ravulizumab compared to eculizumab in adult participants with PNH who were clinically stable after having been treated with eculizumab for at least 6 months.
Trial Locations
Location
Status
Location
Research Site
Duarte, California, United States, 91010
Status
N/A
Location
Research Site
Los Angeles, California, United States, 90089
Status
N/A
Location
Research Site
Baltimore, Maryland, United States, 21205
Status
N/A
Location
Research Site
Detroit, Michigan, United States, 48202
Status
N/A
Location
Research Site
Bronx, New York, United States, 10467
Status
N/A
Location
Research Site
Canberra, Australia, 2605
Status
N/A